A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer. (2020)
Attributed to:
BAG-1: A novel strategy for targeting the androgen receptor splice variants in castrate resistant prostate cancer.
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/j.annonc.2020.01.074
PubMed Identifier: 32205016
Publication URI: http://europepmc.org/abstract/MED/32205016
Type: Journal Article/Review
Volume: 31
Parent Publication: Annals of oncology : official journal of the European Society for Medical Oncology
Issue: 5
ISSN: 0923-7534